Drugs that contain Melphalan Hydrochloride
1. Evomela patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410077 | ACROTECH BIOPHARMA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US9200088 | ACROTECH BIOPHARMA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US11020363 | ACROTECH BIOPHARMA | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(6 years from now) | |
| US10864183 | ACROTECH BIOPHARMA | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(6 years from now) | |
| US10940128 | ACROTECH BIOPHARMA | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
Jun, 2030
(6 years from now) | |
| US9493582 | ACROTECH BIOPHARMA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| US10040872 | ACROTECH BIOPHARMA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Jan, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Mar 10, 2023 |
| Orphan Drug Exclusivity(ODE-110) | Mar 10, 2023 |
Market Authorisation Date: 10 March, 2016
Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma
Dosage: POWDER;INTRAVENOUS
EVOMELA family patents
2. Hepzato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11633528 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(8 years from now) | |
| US11241522 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(8 years from now) | |
| US10569004 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(8 years from now) | |
| US10098997 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(8 years from now) | |
| US10369264 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Nov, 2032
(8 years from now) | |
| US11083831 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Dec, 2032
(8 years from now) | |
| US11833286 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Dec, 2032
(8 years from now) | |
| US10195334 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Jan, 2033
(8 years from now) | |
| US9314561 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Feb, 2034
(9 years from now) | |
| US9707331 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Sep, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 14, 2026 |
| Orphan Drug Exclusivity(ODE-438) | Aug 14, 2030 |
Market Authorisation Date: 14 August, 2023
Treatment: A percutaneous hepatic perfusion procedure for treating a patient with uveal melanoma with unresectable hepatic metastases; A method of treating a patient with uveal melanoma with unresectable hepatic...
Dosage: POWDER;INTRA-ARTERIAL
HEPZATO family patents
3. Melphalan Hydrochloride patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537520 | APOTEX | Stable liquid formulations of melphalan |
Jun, 2036
(12 years from now) | |
Market Authorisation Date: 18 August, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
MELPHALAN HYDROCHLORIDE family patents